Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07037901 | A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis | PHASE2 | RECRUITING | 220 | — | — | Jun 17, 2025 | Oct 1, 2027 | Feb 19, 2026 | 23 | United States, Canada |
| Arm | Type | Description |
|---|---|---|
| IMG-007 dose 1 | EXPERIMENTAL | Subcutaneous injection as per protocol. |
| IMG-007 dose 2 | EXPERIMENTAL | Subcutaneous injection as per protocol. |
| IMG-007 dose 3 | EXPERIMENTAL | Subcutaneous injection as per protocol. |
| Placebo Crossover | PLACEBO_COMPARATOR | Subcutaneous placebo injection as per protocol. At crossover, IMG-007 subcutaneous injection as per protocol. |
| Name | Type | Description |
|---|---|---|
| IMG-007 | DRUG | Participants will receive IMG-007 subcutaneously. |
| Placebo | DRUG | Participants will receive a placebo subcutaneously. |
Key Inclusion Criteria: * Moderate-to-severe AD * Documented history of inadequate response or lack of tolerability to a stable regimen of one or more topical treatment before the Screening visit, or for whom topical treatments are otherwise inadvisable * Female participants who are not pregnant or...